In the Original Investigation titled “Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis,”1 there were errors in the coloring and line labels of Figure 2, panels B and C. The article has been corrected online.
References
- 1.Joshi TP, Duvic M, Torres-Cabala CA, Tschen JA. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131-1141. doi: 10.1001/jamadermatol.2022.2909 [DOI] [PMC free article] [PubMed] [Google Scholar]